After huge (media) interest in the run-up, the approval process for Valneva’s Corona vaccine has now started in the UK. In the rolling process, the authorities are constantly supplied with new information from the ongoing trials and, in the best case, approval is expected before the end of the year.
The prospect of this boosted Valneva’s shares by around ten percent at the start of the week, and it’s not as if the stock had fared badly in the run-up. A year ago, it was trading at less than five euros; now the price is around 22 euros.
This looks really good
So far, the bulls are not even thinking of letting go of what they have achieved. It is true that prices are currently fluctuating somewhat, and Wednesday initially began with slight price losses. This week, however, they did not even come close to the 20-euro mark again, which was only conquered at the end of August.
The mood among shareholders remains hopeful, and there are many good reasons for this. The Austrian-French company is the only one in Europe working on a dead vaccine against Corona and many observers expect a lot from this project.
Everything remains open with the Valneva share
As usual, investments in Valneva stock are a big bet. Shareholders have to accept many imponderables. For example, whether approval will be granted at all. The fact that such a thing can also go very badly wrong was shown not so long ago by the example of CureVac, albeit with an mRNA vaccine.
Even in the event of successful approval, however, it remains to be seen how potential customers will behave. The expectation on the markets is that the dead vaccine will be able to convince many skeptics to vaccinate who have so far refused mRNA vaccines. However, it remains to be seen whether this will actually happen.